Evidence map›Paper›PMID 39411530›Full record

ArticleACS medicinal chemistry letters2024

Synthesis and In Vivo Profiling of Desymmetrized Antimalarial Trioxolanes with Diverse Carbamate Side Chains.

Matthew T Klope, Juan A Tapia Cardona, Jun Chen, Ryan L Gonciarz, Ke Cheng, Priyadarshini Jaishankar, Julie Kim, Jenny Legac, Philip J Rosenthal, Adam R Renslo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Double Mutations inbioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew T KlopeDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Juan A Tapia CardonaDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Jun ChenDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Ryan L GonciarzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Ke ChengDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID https://orcid.org/0000-0001-5057-3120
Priyadarshini JaishankarDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Julie KimDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.
Jenny LegacDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94143, United States.
Philip J RosenthalDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94143, United States.
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States.ORCID https://orcid.org/0000-0002-1240-2846

Funding

Chemical Methods for Ferrous Iron Dependent Drug DeliveryR01AI105106 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RENSLO, ADAM R · 2013 to 2022
$4.6M
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
NIAID NIH HHS R01 AI105106NIGMS NIH HHS T32 GM145460
6 · The paper itself

Abstract

The recent withdrawal of artefenomel from clinical development leaves no endoperoxide-class agents in the antimalarial pipeline. Synthetic endoperoxides with a desymmetrized structure have demonstrated promising physiochemical and

Identifiers

PMID39411530
PMCPMC11472393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.